Peter Kolchinsky 5/31/22 Peter Kolchinsky 5/31/22

Biotech’s Dulcius Ex Asperis: The Way Through This Downturn (Bionic Reading)

The biotech sector is experiencing the most severe downturn of at least the last 20 years. There have been many other downturns in the more recent past, but this one is different. Here Peter Kolchinsky discusses why - and how we’ll rebound.

Chris Morrison 5/25/22 Chris Morrison 5/25/22

Step-by-step price discovery for private companies

There is a simple process by which any board of a private company can ensure that it finds a price at which its existing investors and new ones will give it the funding it wants. Aspects of this process are relevant whether a company is heading into a private financing or preparing for an IPO. Check it out here.

© Copyright 2001-2023 RA Capital Management, L.P. This website is for informational purposes only and does not constitute an offer to provide investment advisory or other services by RA Capital Management, L.P. (“RA Capital”). Nothing contained on the website constitutes investment advice, and the views expressed should not be taken as advice to buy, sell, or hold any security or as an endorsement of any security or company. In preparing the information contained in this website, RA Capital has not taken into account the investment needs, objectives, and financial circumstances of any particular investor, and investments and companies referenced may not be suitable for all investors. Any views expressed were prepared based upon information available and believed to be reliable at the time such views were written. RA Capital makes no guarantees as to their accuracy or completeness. All information is subject to change and may quickly become unreliable for various reasons, including changes in market conditions or economic circumstances. By accessing this website, you agree not to copy, reproduce, republish, upload, post, transmit, alter, or distribute, in any way, content or materials from this website in any manner inconsistent with the purposes for which it is offered without the prior written consent of RA Capital.